立体定向放射治疗早期非小细胞肺癌的研究进展

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (625 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Stereotactic radiotherapy (SBRT) has become the standard treatment for medically inoperable early non-small cell lung cancer (NSCLC), providing local tumor control effects comparable to surgery. For operable patients with early-stage NSCLC, the efficacy of SBRT is the same or even better than surgery. With the advancement of Phase Ⅱclinical trials, the understanding of the radiobiological characteristics of SBRT, treatment techniques and related methods, dose limits for normal organs/tissues, major factors affecting efficacy, SBRT-induced immune effects, and distant effects and other aspects is deeper, these provide a reliable basis for the clinical application of SBRT. This article reviews the recent advances in SBRT for NSCLC in these areas.

Key words： Stereotactic body radiation therapy Early-stage Non-small cell lung cancer Research progress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DENG Xiaoxi GE Wei

Cite this article:

DENG Xiaoxi GE Wei. Research advances for Stereotactic body radiation therapy in early stage Non-small cell lung cancer[J]. 中国医药导报, 2018, 15(33): 28-31,39.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I33/28

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2018 [J]. CA Cancer J Clin，2018，68（1）：7-30.
[2] Chen Z，Fillmore CM，Hammerman PS，et al. Non-small-cell lung cancers：a heterogeneous set of diseases [J]. Nat Rev Cancer，2014，14（8）：535-546.
[3] Videtic G，Donington J，Giuliani M，et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer：executive summary of an ASTRO evidence-based guideline [J]. Pract Radiat Oncol，2017，7（5）：295-301.
[4] Chang JY，Senan S，Paul MA，et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer：a pooled analysis of two randomised trials [J]. Lancet Oncol，2015，16（6）：630-637.
[5] Senthi S，Lagerwaard FJ，Haasbeek CJ，et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer：a retrospective analysis [J]. Lancet Oncol，2012，13（8）：802-809.
[6] Chang JY，Senan S，Paul MA，et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer：a pooled analysis of two randomised trials [J]. Lancet Oncol，2015，16（6）：630-637.
[7] 庞笑珍，朱健，丁嘉佩，等.立体定向放射治疗肺癌患者不良反应观察及护理[J].中国现代医生，2017，55（28）：134-137.
[8] Nahum AE. The radiobiology of hypofractionation [J]. Clin Oncol，2015，27（5）：260-269.
[9] Brown JM，Brenner DJ，Carlson DJ. Dose escalation，not "new biology，"can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer [J]. Int J Radiat Oncol Biol Phys，2013，85（5）：1159-1160.
[10] Ruggieri R，Stavrev P，Naccarato S，et al. Optimal dose and fraction number in SBRT of lung tumours：a radiobiological analysis [J]. Phys Med，2017，44：188-195.
[11] Macmahon H，Naidich DP，Goo JM，et al. Guidelines for management of incidental pulmonary nodules detected on CT images：from the fleischner society 2017 [J]. Radiology，2017，284（1）：228-243.
[12] Ma L，Xiang J. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer：a meta-analysis [J]. Thorac Cancer，2016，7（4）：442-451.
[13] Verstegen NE，Lagerwaard FJ，Haasbeek CJA，et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC：Comparison with a contemporaneous cohort with pathologically proven disease [J]. Radiother Oncol，2011，101（2）：250-254.
[14] Wang P，Zhang D，Guo X，et al. A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly [J]. Medicine，2016，95（52）：e5723.
[15] Vansteenkiste J，Crino L，Dooms C，et al. 2nd ESMO Consensus Conference on Lung Cancer：early-stage non-small-cell lung cancer consensus on diagnosis，treatment and follow-up [J]. Ann Oncol，2014，25（8）：1462-1474.
[16] 孟玲玲，邸玉鹏，杜乐辉，等.老年早期非小细胞肺癌立体定向放射治疗的疗效及生活质量观察[J].中国医学装备，2018，15（7）：27-32.
[17] Jaffray DA. Image-guided radiotherapy：from current concept to future perspectives [J]. Nat Rev Clin Oncol，2012， 9（12）：688-699.
[18] 刘胜林，张强，张盛.构建X射线立体定向放射治疗设备评价体系的研究[J].中国医学装备，2016，13（11）：142-144.
[19] Nagata Y，Hiraoka M，Shibata T，et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer：Japan clinical oncology group study JCOG0403 [J]. Int J Radiat Oncol Biol Phys，2015，93（5）：989-996.
[20] 孙冰，张玉蛟.放射外科在MD安德森肿瘤中心的实践及进展[J].中华放射医学与防护杂志，2016，36（10）：721-727.
[21] Ge H，Cai J，Kelsey CR，et al. Quantification and minimization of uncertainties of internal target volume for stereotactic body radiation therapy of lung cancer [J]. Int J Radiat Oncol Biol Phys，2013，85（2）：438-443.
[22] Hill MA，Thompson JM，Kavanagh A，et al. The development of technology for effective respiratory-gated irradiation using an image-guided small animal irradiator [J]. Radiat Res，2017，188（3）：247-263.
[23] Baine MJ，Verma V，Schonewolf CA，et al. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer [J]. Lung Cancer，2018，118：20-26.
[24] Verma V，Shostrom VK，Zhen W，et al. Influence of fractionation scheme and tumor location on toxicities after stereotactic body radiation therapy for large（≥5 cm） non-small cell lung cancer：a multi-institutional analysis [J]. Int J Radiat Oncol Biol Phys，2017，97（4）：778-785.
[25] Senthi S，Lagerwaard FJ，Haasbeek CJ，et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer：a retrospective analysis [J]. Lancet Oncol， 2012，13（8）：802-809.
[26] Golden EB，Apetoh L. Radiotherapy and immunogenic cell death [J]. Semin Radiat Oncol，2015，25（1）：11-17.
[27] Gameiro SR，Jammeh ML，Wattenberg MM，et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure，resulting in enhanced T-cell killing [J]. Oncotarget，2014， 5（2）：403-416.
[28] Reynders K，Illidge T，Siva S，et al. The abscopal effect of local radiotherapy：using immunotherapy to make a rare event clinically relevant [J]. Cancer Treat Rev，2015， 41（6）：503-510.
[29] 陈开容，王潇，牟艳，等.立体定向放疗对Ⅰ期非小细胞肺癌患者生存质量及预后影响因素分析[J].临床和实验医学杂志，2018，17（10）：1067-1070.
[30] 胡晓楠，张建鑫，郝春成，等.体部立体定向放射治疗Ⅰ期周围型肺癌50例疗效观察[J].疑难病杂志，2016，15（10）：1074-1077.